Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage

R. Houston Thompson, Xingxing Zang, Christine M. Lohse, Bradley C. Leibovich, Susan F. Slovin, Victor E. Reuter, John C. Cheville, Michael L. Blute, Paul Russo, Eugene D Kwon, James P. Allison

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

B7x is the newest member of the B7-CD28 family and is thought to dampen immune responses via negative costimulation. Tumor expression of B7x was recently described in renal cell carcinoma (RCC) and was associated with poor outcome. We developed an assay to detect serum-soluble B7x (sB7x) and investigated 101 patients with clear cell RCC who underwent nephrectomy between 2003 and 2007. For controls, we obtained serum from 101 sex-matched blood donors within the same age range. Following an ELISA for sB7x, detectable levels (>0.1 ng/mL) of sB7x were observed in 53 RCC patients compared with 18 controls (P < 0.001). Median (range) concentrations of sB7x for RCC patients and controls were 14.4 ng/mL (0.1-56.9) and 2.7 ng/mL (0.2-37.1), respectively. For RCC patients with detectable sB7x, median levels were significantly higher for patients with a tumor thrombus (19.2 versus 6.6 ng/mL; P = 0.007), positive lymph nodes (41.3 versus 10.3 ng/mL; P = 0.018), and distant metastases at nephrectomy (43.3 versus 8.5 ng/mL; P = 0.002) and tended to be higher in patients with high-grade tumors (18.8 versus 8.5; P = 0.090). Additionally, median sB7x levels for tumor-node-metastasis stage I to IV RCC were 6.6, 10.3, 14.5, and 43.3 ng/mL, respectively (P = 0.012). In this first evaluation of sB7x in RCC, we show that RCC patients are more likely to have detectable sB7x compared with controls and higher sB7x levels correlate with advanced tumor stage. These early results merit further investigation of this serum marker for potential diagnostic and prognostic purposes.

Original languageEnglish (US)
Pages (from-to)6054-6058
Number of pages5
JournalCancer Research
Volume68
Issue number15
DOIs
StatePublished - Aug 1 2008

Fingerprint

Renal Cell Carcinoma
Serum
Neoplasms
Nephrectomy
Neoplasm Metastasis
Blood Donors
Thrombosis
Biomarkers
Lymph Nodes
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thompson, R. H., Zang, X., Lohse, C. M., Leibovich, B. C., Slovin, S. F., Reuter, V. E., ... Allison, J. P. (2008). Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Research, 68(15), 6054-6058. https://doi.org/10.1158/0008-5472.CAN-08-0869

Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. / Thompson, R. Houston; Zang, Xingxing; Lohse, Christine M.; Leibovich, Bradley C.; Slovin, Susan F.; Reuter, Victor E.; Cheville, John C.; Blute, Michael L.; Russo, Paul; Kwon, Eugene D; Allison, James P.

In: Cancer Research, Vol. 68, No. 15, 01.08.2008, p. 6054-6058.

Research output: Contribution to journalArticle

Thompson, RH, Zang, X, Lohse, CM, Leibovich, BC, Slovin, SF, Reuter, VE, Cheville, JC, Blute, ML, Russo, P, Kwon, ED & Allison, JP 2008, 'Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage', Cancer Research, vol. 68, no. 15, pp. 6054-6058. https://doi.org/10.1158/0008-5472.CAN-08-0869
Thompson, R. Houston ; Zang, Xingxing ; Lohse, Christine M. ; Leibovich, Bradley C. ; Slovin, Susan F. ; Reuter, Victor E. ; Cheville, John C. ; Blute, Michael L. ; Russo, Paul ; Kwon, Eugene D ; Allison, James P. / Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. In: Cancer Research. 2008 ; Vol. 68, No. 15. pp. 6054-6058.
@article{8d7a55d838dd449bbb1b40caffa6cfc3,
title = "Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage",
abstract = "B7x is the newest member of the B7-CD28 family and is thought to dampen immune responses via negative costimulation. Tumor expression of B7x was recently described in renal cell carcinoma (RCC) and was associated with poor outcome. We developed an assay to detect serum-soluble B7x (sB7x) and investigated 101 patients with clear cell RCC who underwent nephrectomy between 2003 and 2007. For controls, we obtained serum from 101 sex-matched blood donors within the same age range. Following an ELISA for sB7x, detectable levels (>0.1 ng/mL) of sB7x were observed in 53 RCC patients compared with 18 controls (P < 0.001). Median (range) concentrations of sB7x for RCC patients and controls were 14.4 ng/mL (0.1-56.9) and 2.7 ng/mL (0.2-37.1), respectively. For RCC patients with detectable sB7x, median levels were significantly higher for patients with a tumor thrombus (19.2 versus 6.6 ng/mL; P = 0.007), positive lymph nodes (41.3 versus 10.3 ng/mL; P = 0.018), and distant metastases at nephrectomy (43.3 versus 8.5 ng/mL; P = 0.002) and tended to be higher in patients with high-grade tumors (18.8 versus 8.5; P = 0.090). Additionally, median sB7x levels for tumor-node-metastasis stage I to IV RCC were 6.6, 10.3, 14.5, and 43.3 ng/mL, respectively (P = 0.012). In this first evaluation of sB7x in RCC, we show that RCC patients are more likely to have detectable sB7x compared with controls and higher sB7x levels correlate with advanced tumor stage. These early results merit further investigation of this serum marker for potential diagnostic and prognostic purposes.",
author = "Thompson, {R. Houston} and Xingxing Zang and Lohse, {Christine M.} and Leibovich, {Bradley C.} and Slovin, {Susan F.} and Reuter, {Victor E.} and Cheville, {John C.} and Blute, {Michael L.} and Paul Russo and Kwon, {Eugene D} and Allison, {James P.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-08-0869",
language = "English (US)",
volume = "68",
pages = "6054--6058",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage

AU - Thompson, R. Houston

AU - Zang, Xingxing

AU - Lohse, Christine M.

AU - Leibovich, Bradley C.

AU - Slovin, Susan F.

AU - Reuter, Victor E.

AU - Cheville, John C.

AU - Blute, Michael L.

AU - Russo, Paul

AU - Kwon, Eugene D

AU - Allison, James P.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - B7x is the newest member of the B7-CD28 family and is thought to dampen immune responses via negative costimulation. Tumor expression of B7x was recently described in renal cell carcinoma (RCC) and was associated with poor outcome. We developed an assay to detect serum-soluble B7x (sB7x) and investigated 101 patients with clear cell RCC who underwent nephrectomy between 2003 and 2007. For controls, we obtained serum from 101 sex-matched blood donors within the same age range. Following an ELISA for sB7x, detectable levels (>0.1 ng/mL) of sB7x were observed in 53 RCC patients compared with 18 controls (P < 0.001). Median (range) concentrations of sB7x for RCC patients and controls were 14.4 ng/mL (0.1-56.9) and 2.7 ng/mL (0.2-37.1), respectively. For RCC patients with detectable sB7x, median levels were significantly higher for patients with a tumor thrombus (19.2 versus 6.6 ng/mL; P = 0.007), positive lymph nodes (41.3 versus 10.3 ng/mL; P = 0.018), and distant metastases at nephrectomy (43.3 versus 8.5 ng/mL; P = 0.002) and tended to be higher in patients with high-grade tumors (18.8 versus 8.5; P = 0.090). Additionally, median sB7x levels for tumor-node-metastasis stage I to IV RCC were 6.6, 10.3, 14.5, and 43.3 ng/mL, respectively (P = 0.012). In this first evaluation of sB7x in RCC, we show that RCC patients are more likely to have detectable sB7x compared with controls and higher sB7x levels correlate with advanced tumor stage. These early results merit further investigation of this serum marker for potential diagnostic and prognostic purposes.

AB - B7x is the newest member of the B7-CD28 family and is thought to dampen immune responses via negative costimulation. Tumor expression of B7x was recently described in renal cell carcinoma (RCC) and was associated with poor outcome. We developed an assay to detect serum-soluble B7x (sB7x) and investigated 101 patients with clear cell RCC who underwent nephrectomy between 2003 and 2007. For controls, we obtained serum from 101 sex-matched blood donors within the same age range. Following an ELISA for sB7x, detectable levels (>0.1 ng/mL) of sB7x were observed in 53 RCC patients compared with 18 controls (P < 0.001). Median (range) concentrations of sB7x for RCC patients and controls were 14.4 ng/mL (0.1-56.9) and 2.7 ng/mL (0.2-37.1), respectively. For RCC patients with detectable sB7x, median levels were significantly higher for patients with a tumor thrombus (19.2 versus 6.6 ng/mL; P = 0.007), positive lymph nodes (41.3 versus 10.3 ng/mL; P = 0.018), and distant metastases at nephrectomy (43.3 versus 8.5 ng/mL; P = 0.002) and tended to be higher in patients with high-grade tumors (18.8 versus 8.5; P = 0.090). Additionally, median sB7x levels for tumor-node-metastasis stage I to IV RCC were 6.6, 10.3, 14.5, and 43.3 ng/mL, respectively (P = 0.012). In this first evaluation of sB7x in RCC, we show that RCC patients are more likely to have detectable sB7x compared with controls and higher sB7x levels correlate with advanced tumor stage. These early results merit further investigation of this serum marker for potential diagnostic and prognostic purposes.

UR - http://www.scopus.com/inward/record.url?scp=51049113616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049113616&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-0869

DO - 10.1158/0008-5472.CAN-08-0869

M3 - Article

C2 - 18676826

AN - SCOPUS:51049113616

VL - 68

SP - 6054

EP - 6058

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -